I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The applicant Fujisawa GmbH submitted on 28 July 2000 an application for Marketing Authorisation 
to the European Agency for the Evaluation of Medicinal Products (EMEA) for Protopic, through the 
centralised procedure. After agreement by the CPMP on 16 March 2000, this medicinal product has 
been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of  22  July  1993  as 
amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Mary Teeling 
Co-Rapporteur:  Prof. Hans Winkler 
Dr. Patrick Salmon 
Prof. Heribert Pittner 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
Protopic has been given a Marketing Authorisation in Japan on 16 June 1999, in USA on 8 December 
2000 and in Canada on 25 June 2001. 
2. 
Steps taken for the assessment of the product 
•  The procedure started on 16 August 2000. 
•  The Rapporteur's first Assessment Report was circulated to all CPMP members on 10 November 
2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  20 
November 2000. 
•  During  the  meeting  on  12-14  December  2000,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
company on 15 December 2000. 
•  The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  12  June 
2001. 
•  The Rapporteur and Co-Rapporteur circulated the response Assessment Report on the company’s 
responses to the List of Questions to all CPMP members on 15 August 2001. 
•  During the CPMP meeting on 18-20 September 2001, the CPMP agreed on a List of Outstanding 
Issues. 
•  Written explanations were provided by the applicant on 1 October 2001. 
•  The  Rapporteur  and  Co-Rapporteur  circulated  a  Joint  Assessment  Report  on  the  company’s 
responses to the List of Outstanding Issues to all CPMP members on 10 October 2001. 
•  During  the  CPMP  meeting  on  16-18  October  2001,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
•  During the meeting on 16-18 October 2001, the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Protopic on 18 October 2001. 
CPMP/3447/01 
1/2 
EMEA 2002 
 
 
II  GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION 
1. 
Manufacturing authorisation holder 
Manufacturer of the active substance 
Fujisawa Pharmaceutical Co., Ltd., Toyama Plant, 2-178 Kojin-cho, Toyama 930, Japan. 
Manufacturers of the finished product 
Bulk product manufacturing and tube filling 
Fujisawa Healthcare, Inc., 3125 Staley Road, Grand Island, NY 14072, USA. 
Finished product manufacture/packaging (carton and package leaflet) 
Fujisawa Ireland Ltd., Killorglin, Co. Kerry, Ireland. 
Manufacturer responsible for batch release 
Fujisawa Ireland Ltd., Killorglin, Co. Kerry, Ireland. 
Manufacturing Authorisation issued on 27th June 2000 by the Irish Medicines Board (Earlsfort Centre, 
Earlsfort Terrace, Dublin) 
2. 
Conditions or restrictions regarding supply and use 
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product 
Characteristic, 4.2). 
3. 
Follow-up measures of the Marketing Authorisation Holder  
As requested by the CPMP, the Applicant agreed to submit follow-up measures related to the clinical 
part. 
CPMP/3447/01 
2/2 
EMEA 2002 
 
 
 
 
 
 
 
